{
  "source": "PA-Notification-Mektovi.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1256-9\nProgram Prior Authorization/Notification\nMedication Mektovi® (binimetinib)\nP&T Approval Date 8/2018, 9/2019, 6/2020, 6/2021, 8/2021, 8/2022, 8/2023, 12/2023,\n12/2024\nEffective Date 3/1/2025\n1. Background:\nMektovi® (binimetinib) is a kinase inhibitor indicated, in combination with Braftovi®\n(encorafenib), for the treatment of patients with unresectable or metastatic melanoma with a\nBRAF V600E or V600K mutation and for the treatment of adult patients with metastatic non-\nsmall cell lung cancer (NSCLC) with a BRAF V600E mutation.\nThe National Cancer Comprehensive Network (NCCN) guideline also recommends use of\nMektovi in melanoma for NRAS-mutated tumors that have progressed after prior immune\ncheckpoint inhibitor therapy, recurrent or advanced NSCLC with a BRAF V600E mutation,\nLangerhans Cell Histiocytosis, low-grade serous carcinoma, and in combination with imatinib\n(Gleevec) for succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST)\nwith gross residual disease (R2 resection), unresectable primary disease, tumor rupture or\nrecurrent/metastatic disease.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age\nof 19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Mektovi will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Melanoma\n1. Initial Authorization\na. Mektovi will be approved based on all of the following criteria:\n© 2024 UnitedHealthcare Serv",
    "s than 19 years of age\nAuthorization will be issued for 12 months.\nB. Melanoma\n1. Initial Authorization\na. Mektovi will be approved based on all of the following criteria:\n© 2024 UnitedHealthcare Services, Inc.\n1\n(1) Diagnosis of melanoma\n-AND-\n(2) Disease is one of the following:\n(a) Unresectable\n(b) Metastatic\n-AND-\n(3) One of the following:\n(a) Both of the following\ni. Patient is positive for BRAFV600 mutation\n-AND-\nii. Used in combination with Braftovi (encorafenib)\n-OR-\n(b) Both of the following:\ni. Patient is positive for NRAS mutation\n-AND-\nii. Progression after prior immune checkpoint inhibitor therapy\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Mektovi will be approved based on both of the following criteria:\n(1) Patient does not show evidence of progressive disease while on Mektovi therapy\n-AND-\n(2) One of the following:\n(a) Both of the following:\ni. BRAFV600 mutation positive\n© 2024 UnitedHealthcare Services, Inc.\n2\n-AND-\nii. Used in combination with Braftovi (encorafenib)\n-OR-\n(b) NRAS-mutated tumor\nAuthorization will be issued for 12 months.\nC. Histiocytic Neoplasms\n1. Initial Authorization\na. Mektovi will be approved based on both the following criteria:\n(1) One of the following diagnoses:\n(a) Multisystem Langerhans Cell Histiocytosis\n(b) Single-system lung Langerhans Cell Histiocytosis\n(c) Langerhans Cell Histiocytosis with CNS lesions\n-AND-\n(2) One of the following:\n(a) Disease is positive for mitogen-activated protein (MAP) kinase pathway\nmutation\n(b) No other detectable/actionable mutation\n(c) Testing is not available\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Mektovi will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Mektovi therapy.\nAuthorization will be issued for 12 months.\nD. Serous Carcinoma\n1. Initial Authorization\na. Mektovi will be approved based on both the following criteria:\n(1) Diagnosis of low-grade serous carcinoma\n-AND-\n© ",
    "zation will be issued for 12 months.\nD. Serous Carcinoma\n1. Initial Authorization\na. Mektovi will be approved based on both the following criteria:\n(1) Diagnosis of low-grade serous carcinoma\n-AND-\n© 2024 UnitedHealthcare Services, Inc.\n3\n(2) Disease is recurrent\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Mektovi will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Mektovi therapy.\nAuthorization will be issued for 12 months.\nE. Gastrointestinal Stromal Tumor (GIST)\n1. Initial Authorization\na. Mektovi will be approved based on all the following criteria:\n(1) Diagnosis of succinate dehydrogenase (SDH)-deficient gastrointestinal stromal\ntumor (GIST)\n-AND-\n(2) Disease is one of the following:\n(a) Gross residual disease (R2 resection)\n(b) Unresectable primary disease\n(c) Tumor rupture\n(d) Progressive\n(e) Recurrent\n(f) Metastatic\n-AND-\n(3) Used in combination with imatinib mesylate (Gleevec)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Mektovi will be approved based on both of the following criteria:\n(1) Patient does not show evidence of progressive disease while on Mektovi therapy\n-AND-\n(2) Used in combination with imatinib mesylate (Gleevec)\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n4\nF. Non-Small Cell Lung Cancer\n1. Initial Authorization\na. Mektovi will be approved based on all of the following criteria:\n(1) Diagnosis of non-small cell lung cancer (NSCLC)\n-AND-\n(2) Disease is one of the following:\n(a) Recurrent\n(b) Advanced\n(c) Metastatic\n-AND-\n(3) Patient is positive for BRAFV600 mutation\n-AND-\n(4) Used in combination with Braftovi (encorafenib)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Mektovi will be approved based on both of the following criteria:\n(1) Patient does not show evidence of progressive disease while on Mektovi\ntherapy\n-AND-\n(2) Used in combination with Braftovi (encorafenib)\nAuthori",
    "e approved based on both of the following criteria:\n(1) Patient does not show evidence of progressive disease while on Mektovi\ntherapy\n-AND-\n(2) Used in combination with Braftovi (encorafenib)\nAuthorization will be issued for 12 months.\nG. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category\nof Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n5\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Mektovi [package insert]. Boulder, CO: Array BioPharma Inc.; October 2023.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nwww.nccn.org. Accessed October 21, 2024.\nProgram Prior Authorization/Notification - Mektovi (binimetinib)\nChange Control\n8/2018 New program\n9/2019 Annual review. Updated background and criteria to include NCCN\nrecommended use in BRAF V600 E colorectal cancer. Updated references.\nAdded general NCCN recommended review criteria.\n6/2020 Updated background and criteria. Removed criteria for BRAFV600E\ncolorectal cancer as no longer recommended by NCCN.\n6/2021 Annual review. Added criteria in melanoma for NRAS-mutated tumors.\nUpdated reference.\n8/2021 Updated reauthorization criteria to not require Braftovi combination therapy\nfor NRAS-mutated tumor.\n8/2022 Annual review. Updated background and reference. Added ",
    "ed tumors.\nUpdated reference.\n8/2021 Updated reauthorization criteria to not require Braftovi combination therapy\nfor NRAS-mutated tumor.\n8/2022 Annual review. Updated background and reference. Added criteria per\nNCCN recommendations for histiocytic neoplasms and serous carcinoma.\nAdded state mandate footnote.\n8/2023 Annual review. Added criteria per NCCN recommendations for SDH-\ndeficient GIST. Updated background and reference.\n12/2023 Updated background and criteria to include new FDA approved use in BRAF\nV600E NSCLC. Updated references.\n12/2024 Annual review. Updated formatting of criteria for melanoma and histiocytic\nneoplasms with no change in clinical intent. Added reauthorization\nrequirement that Mektovi must be used in combination with imatinib for\nGIST. For NSCLC, expanded coverage to include recurrent and advanced\ndisease per NCCN recommendation and added reauthorization requirement\nthat Mektovi must be used in combination with Braftovi. Updated\nbackground and references.\n© 2024 UnitedHealthcare Services, Inc.\n6"
  ]
}